Research Papers:

First-in-human study of anticancer immunotherapy drug candidate mobilan: safety, pharmacokinetics and pharmacodynamics in prostate cancer patients

Natalia V. Eremina, Vasily I. Kazey _, Sergey V. Mishugin, Roman V. Leonenkov, Dmitry Y. Pushkar, Vadim L. Mett and Andrei V. Gudkov _

PDF  |  Full Text  |  How to cite  |  Press Release

Oncotarget. 2020; 11:1273-1288. https://doi.org/10.18632/oncotarget.27549

Metrics: PDF 1319 views  |   Full Text 2359 views  |   ?  


Natalia V. Eremina1, Vasily I. Kazey1, Sergey V. Mishugin2, Roman V. Leonenkov3, Dmitry Y. Pushkar4, Vadim L. Mett5 and Andrei V. Gudkov6

1 Panacela Labs LLC, Moscow, Russian Federation

2 D.D. Pletnev Municipal Clinical Hospital, Moscow Department of Healthcare, Moscow, Russian Federation

3 St. Petersburg Clinical Research and Practical Center for Specialized Oncological Medical Care, St. Petersburg, Russian Federation

4 S.I. Spasokukotsky Municipal Clinical Hospital, Moscow Department of Healthcare, Moscow, Russian Federation

5 Buffalo BioLabs LLC, Buffalo, NY, USA

6 Department of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

Correspondence to:

Vasily I. Kazey,email: [email protected]
Andrei V. Gudkov,email: [email protected]

Keywords: prostate cancer; immunotherapy; mobilan; adenoviral vector; intratumor injection

Received: February 10, 2020     Accepted: March 14, 2020     Published: April 07, 2020


Toll-like receptor 5 (TLR5) controls endogenous immune responses to pathogens and is a promising target for pharmacological stimulation of anti-tumor immunity. Mobilan is an innovative gene therapy agent consisting of a non-replicating bicistronic adenovirus directing constitutive expression of human Toll-like receptor 5 (TLR5) and the secreted flagellin-based TLR5 agonist, 502s. In mice, Mobilan injection into prostate tumors resulted in autocrine TLR5 signaling, immune system activation, and suppression of tumor growth and metastasis. Here we report a first-in-human placebo-controlled clinical study of Mobilan aimed at evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of a single intra-prostate injection of Mobilan in early stage prostate cancer patients. Mobilan was safe and well-tolerated at all tested doses; thus, the maximum tolerated dose was not identified. Injection of Mobilan induced signs of self-resolving inflammation not present in placebo-injected patients, including transient elevation of PSA and cytokine (G-CSF, IL-6) levels, and increased lymphoid infiltration in prostate tissue. The highest dose of Mobilan (1011 viral particles) produced the best combination of safety and pharmacodynamic effects. Therefore, Mobilan is well-tolerated and induces the expected pharmacodynamic response in humans. These results support further clinical development of Mobilan as a novel immunotherapy for prostate cancer.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27549